Kymera治疗执行官出售的股票总额超过110 000美元,尽管有“买”分析师评级。 Kymera Therapeutics executives sold shares totaling over $110,000, despite a "buy" analyst rating.

3. 3月3日,Kymera治疗技术公司Jeremy Chadwick和内部人Ellen Chiniara出售公司股份,共计42 112.35美元和68 238.45美元。 Kymera Therapeutics COO Jeremy Chadwick and insider Ellen Chiniara sold company shares on March 3, totaling $42,112.35 and $68,238.45 respectively. Kymera是一家生物制药公司,重点开发能降解致病蛋白质的治疗方法。 Kymera, a biopharmaceutical firm, focuses on developing therapeutics that degrade disease-causing proteins. 尽管最近股票销售和金融计量显示净利润和股本回报为负值,分析师仍给予该公司“购买”评级,目标价格为56.69美元。 Despite recent stock sales and financial metrics showing negative net margin and return on equity, analysts have given the company a "buy" rating with a target price of $56.69.